Caigang Liu

20PUBLICATIONS
32CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersColloid and surface chemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Mar 20, 2026
SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial.

Herui Yao, Min Yan, Zhongsheng Tong

|Oct 08, 2025
CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients.

Haifeng Lin, Yi Han, Lei Guo

|Sep 10, 2025
Correction: Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis.

Xinbo Qiao, Yixiao Zhang, Lisha Sun

|Jul 28, 2025
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study.

Yu Zhang, Shuo Cao, Nan Niu

|Jul 02, 2025
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.

Nan Niu, Jinqi Xue, Guanglei Chen

|May 08, 2025
Correction: Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer.

Yixiao Zhang, Lisha Sun, Haonan Li

Pageof 4

Frequent Collaborators

6 joint publications

Yongliang Yang

5 joint publications

Xinbo Qiao

4 joint publications

Lisha Sun

4 joint publications

Nan Niu